TransEnterix, Inc. (AMEX:TRXC) developer of surgical robotic systems, is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.23 per share.
For the full year, analysts predict revenues of $ 3.13 million, while looking forward to loss of $ 1 per share.
Previous Quarter Performance
TransEnterix, Inc. outlined loss for the second quarter of $ 0.21 per share, from the revenue of $ 0.66 million. The consensus estimates are loss of $ 0.38 per share from $ 0.42 million in revenue. The bottom line results beat street analysts by $ 0.17 or 44.74 percent, at the same time, top line results outshined analysts by $ 0.24 million or 57.14 percent.
Stock Performance
Shares of TransEnterix, Inc. traded up $ 0.01 or 1.99 percent on Wednesday, reaching $ 0.37 with volume of 658.00 thousand shares. TransEnterix, Inc. has traded high as $ 0.38 and has cracked $ 0.35 on the downward trend
The closing price of $ 0.37, representing a 28.57 % increase from the 52 week low of $ 0.28 and a 91.86 % decrease over the 52 week high of $ 4.42.
The company has a market capital of $ 36.78 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
TransEnterix, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.transenterix.com
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also provides SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.
